TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Swedish cohort study found that longer reproductive lifespan and reported menopausal hormone therapy use were associated with more favorable brain MRI markers in women around age 70. The observational findings do not show that estrogen exposure caused the differences or establish that hormone therapy prevents dementia.
A study of 352 cognitively unimpaired Swedish women linked longer reproductive lifespan and menopausal hormone therapy use with more favorable measures of cerebral small vessel disease and white matter integrity on brain imaging. The findings, reported by Anna Marseglia and colleagues in Neurology, show associations rather than proof that estrogen exposure protects the brain or prevents dementia.
The researchers used data from the 1944 Gothenburg H70 birth cohort, examining women who had brain MRI at age 70. Of the 352 participants, 286 returned for an examination five years later. Their mean Mini-Mental State Examination score at the initial assessment was 29.2, consistent with the study’s description of the group as cognitively unimpaired. About 31% were APOE4 carriers, a genetic group examined separately in some analyses.
Researchers defined reproductive lifespan as the interval between age at menarche and age at menopause or oophorectomy. The cohort’s average was 37.1 years. A longer reproductive span was associated with lower odds of having at least two signs of cerebral small vessel disease: the reported odds ratio was 0.92 (95% CI 0.86-0.99). The researchers assessed disease burden using a composite of white matter hyperintensities, lacunes, cerebral microbleeds and perivascular spaces.
Reported menopausal hormone therapy use was associated with lower small vessel disease burden, with an odds ratio of 0.41 (95% CI 0.20-0.81), and with higher white matter integrity (β=0.28, 95% CI 0.06-0.50). Among APOE4 carriers, hormone therapy use was associated with greater thickness in brain regions commonly affected by Alzheimer’s disease (β=0.38, 95% CI 0.01-0.76). These are statistical associations from this cohort, not estimates of treatment effects.
Women who reported both oral contraceptive use earlier in life and menopausal hormone therapy later had the lowest observed small vessel disease burden (OR 0.31, 95% CI 0.12-0.83) and the highest white matter integrity (β=0.45, 95% CI 0.12-0.78), the report said. Overall, 72.7% reported oral contraceptive use and 60.8% reported menopausal hormone therapy. The researchers also described associations with stable cortical thickness and white matter trajectories over time, and fewer perivascular spaces and microbleeds among hormone therapy users.
What the MRI Associations Suggest
The findings add evidence to research into how reproductive and hormonal history may relate to brain aging. Cerebral small vessel disease affects the brain’s small blood vessels, while white matter measures provide information about connections between brain regions. Both are relevant to studies of cognitive aging, but this study did not show that the observed MRI differences translated into lower dementia rates or better day-to-day cognition.
The results may help researchers frame future work around vascular as well as Alzheimer’s-related pathways. In an accompanying editorial, Tracy Madsen of the University of Vermont argued that endogenous and externally supplied estrogen exposure could offer avenues for studying dementia mechanisms. Madsen also cited projections that the lifetime risk of dementia in U.S. women exceeds that in men and that, by 2060, annual new dementia cases among women may exceed those among men by 233,000. Those projections are editorial context, not an outcome measured in the Swedish cohort.
The findings do not amount to a recommendation to start, stop or change hormone treatment. Decisions about menopausal hormone therapy involve individual health factors, and the cohort study cannot determine whether treatment caused the brain imaging patterns it recorded.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Charge 6 Fitness Tracker – Obsidian/Black
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
Hormone Therapy Evidence Has Shifted
Past research has produced differing findings about menopausal hormone therapy and dementia. Early studies raised the possibility of protection, but the Women’s Health Initiative Memory Study reported in 2003 that estrogen-plus-progestin formulations increased the risk of probable dementia among women aged 65 or older. The broader Women’s Health Initiative also linked combined estrogen and progestin with increased breast cancer and heart disease risks, prompting FDA boxed warnings. The source report says the FDA removed those warnings in 2026; that regulatory change does not establish that hormone therapy prevents brain disease.
Use of hormone replacement therapy among postmenopausal women in the United States fell from 26.9% in 1999 to 4.7% in 2020, according to figures cited in the report. More recent research, including autopsy findings and a large U.K. Biobank study, has reported associations between estrogen-only therapy or earlier treatment and some Alzheimer’s or dementia outcomes. Those studies differ in design and cannot be treated as direct confirmation of the Swedish MRI results.
The new analysis focused on women who were cognitively unimpaired at age 70 and relied on reported histories of reproductive events and hormone use. Its results therefore concern associations within a particular cohort, rather than a clinical trial testing therapy or a finding applicable to every woman.
“The lifetime risk of dementia in U.S. women exceeds that of men, and recent projections suggest that by 2060, the number of incident dementia cases in women will surpass that of men by 233,000.”
— Tracy Madsen, University of Vermont, in an accompanying editorial
Limits of the Swedish Cohort
The study was observational, so it cannot show that longer estrogen exposure or hormone therapy produced the differences in brain imaging. Participants reported their hormone histories, which the researchers said could be affected by recall bias or misclassification. The study also lacked detailed information about oral contraceptive and hormone therapy use, limiting analysis of factors such as specific regimens or exposure patterns.
The report does not establish whether the associations predict future dementia, whether they apply to women with cognitive impairment or different backgrounds, or how results vary by the timing and type of hormone treatment. The APOE4 finding came from a subgroup analysis and should not be interpreted as proof of a treatment benefit for carriers. The researchers measured brain imaging markers, not a reduction in diagnosed dementia.
Further Research on Timing and Outcomes
The next step is further research that can test whether the observed relationships hold in larger and more varied groups, while recording hormone type, dose, duration and timing in greater detail. Following participants for longer could help determine whether MRI measures are associated with later cognitive change or dementia diagnoses. The current report does not specify a planned follow-up study or a next publication date.
For now, the findings add a research association, not a clinical directive. Researchers and clinicians will need evidence that accounts for treatment differences and health risks before drawing conclusions about whether hormone therapy changes long-term brain outcomes.
Key Questions
What did the Swedish study find?
In a cohort of 352 cognitively unimpaired women, longer reproductive lifespan and reported menopausal hormone therapy use were associated with more favorable measures of small vessel disease or white matter integrity. The study did not prove that hormone exposure caused those findings.
Does the study show that hormone therapy prevents dementia?
No. The researchers assessed brain MRI measures and reported associations. They did not establish that hormone therapy prevents dementia or reduces diagnosed dementia risk.
How was lifetime estrogen exposure represented?
The analysis included reproductive lifespan, calculated from age at menarche to age at menopause or oophorectomy, along with reported oral contraceptive and menopausal hormone therapy use. The researchers said detailed information about medication use was lacking.
What were the main limitations?
The study was observational, involved a specific Swedish cohort, and relied on participants’ reports of hormone history. The authors said recall bias and misclassification were possible, and the analysis cannot establish cause and effect.
Should women change hormone treatment because of these results?
The study does not provide a basis for starting, stopping or changing treatment. Decisions about menopausal hormone therapy should be discussed with a qualified health professional who can consider an individual’s circumstances and risks.
Source: medpagetoday.com
